P2X7-Regulated Protection from Exacerbations and Loss of Control Is Independent of Asthma Maintenance Therapy
- 1 January 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 187 (1) , 28-33
Abstract
Rationale: The function of the P2X7 nucleotide receptor protects against exacerbation in people with mild-intermittent asthma during viral illnesses, but the impact of disease severity and maintenance therapy has not been studied. Objectives: To evaluate the association between P2X7, asthma exacerbations, and incomplete symptom control in a more diverse population. Methods: A matched P2RX7 genetic case-control was performed with samples from Asthma Clinical Research Network trial participants enrolled before July 2006, and P2X7 pore activity was determined in whole blood samples as an ancillary study to two trials completed subsequently. Measurements and Main Results: A total of 187 exacerbations were studied in 742 subjects, and the change in asthma symptom burden was studied in an additional 110 subjects during a trial of inhaled corticosteroids (ICS) dose optimization. African American carriers of the minor G allele of the rs2230911 loss-of-function single nucleotide polymorphism were more likely to have a history of prednisone use in the previous 12 months, with adjustment for ICS and long-acting β2-agonists use (odds ratio, 2.7; 95% confidence interval, 1.2–6.2; P = 0.018). Despite medium-dose ICS, attenuated pore function predicted earlier exacerbations in incompletely controlled patients with moderate asthma (hazard ratio, 3.2; confidence interval, 1.1–9.3; P = 0.033). After establishing control with low-dose ICS in patients with mild asthma, those with attenuated pore function had more asthma symptoms, rescue albuterol use, and FEV1 reversal (P < 0.001, 0.03, and 0.03, respectively) during the ICS adjustment phase. Conclusions: P2X7 pore function protects against exacerbations of asthma and loss of control, independent of baseline severity and the maintenance therapy.Keywords
This publication has 44 references indexed in Scilit:
- Rhinovirus-Induced IL-1β Release from Bronchial Epithelial Cells Is Independent of Functional P2X7American Journal of Respiratory Cell and Molecular Biology, 2012
- A trial of clarithromycin for the treatment of suboptimally controlled asthmaJournal of Allergy and Clinical Immunology, 2010
- Two haplotypes of the P2X 7 receptor containing the Ala‐348 to Thr polymorphism exhibit a gain‐of‐function effect and enhanced interleukin‐1β secretionThe FASEB Journal, 2010
- Approaches for Evaluating Rare Polymorphisms in Genetic Association StudiesHuman Heredity, 2010
- Genetics of the P2X7 receptor and human diseasePurinergic Signalling, 2009
- Alveolar macrophage phagocytosis is impaired in children with poorly controlled asthmaJournal of Allergy and Clinical Immunology, 2008
- Standardized method to minimize variability in a functional P2X7flow cytometric assay for a multi-center clinical trialCytometry Part B: Clinical Cytometry, 2008
- Direct labelling of the human P2X7receptor and identification of positive and negative cooperativity of bindingBritish Journal of Pharmacology, 2007
- Guideline-defining asthma clinical trials of the National Heart, Lung, and Blood Institute's Asthma Clinical Research Network and Childhood Asthma Research and Education NetworkJournal of Allergy and Clinical Immunology, 2007
- Significant linkage to chromosome 12q24.32-q24.33 and identification of SFRS8 as a possible asthma susceptibility geneThorax, 2006